U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07399821) titled 'An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma' on Nov. 27, 2025.
Brief Summary: This is a non-randomized, open label phase Ib/II dose-escalation and expansion study designed to define the recommended dose of anti-GD2-800CW in pediatric neuroblastoma patients. The aim of this imaging study is to determine a safe and effective dose of anti-GD2-800CW for intra-operative detection of neuroblastoma using NIR fluorescence.
Study Start Date: Nov. 05, 2025
Study Type: INTERVENTIONAL
Condition:
Neuroblastoma
Intervention:
DRUG: anti-GD2-800CW
Participants will receive a single dose of anti-GD2-800CW 96 hours prior ...